. . . . . . . . . . . "RLZ"@en . . . "investigational"@en . "# Mae T, Inaba T, Konishi E, Hosoe K, Hidaka T: Identification of enzymes responsible for rifalazil metabolism in human liver microsomes. Xenobiotica. 2000 Jun;30(6):565-74. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10923859 # Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI: Development potential of rifalazil. Expert Opin Investig Drugs. 2003 Feb;12(2):255-71. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12556219"@en . "129791-92-0"@en . . . . . . . . . . . "KRM-1648"@en . . . " "@en . . "Benzoxazinorifamycin"@en . "Benzoxazinorifamycin (trade name rifalazil) is a derivative of the antibiotic rifamycin. It is being investigated by ActivBiotics for the treatment of various bacterial infections."@en . . . . . "The potent antimycobacterial activity of benzoxazinorifamycin is due to inhibition of bacterial RNA polymerase."@en . . "Investigated for use/treatment in atherosclerosis, bacterial infection, and peripheral vascular disease."@en . "Bacteria"@en . .